SynuCa Therapeutics

Executive Summary

SynuCa Therapeutics is a Danish biotech company founded in 2020, specializing in small molecule therapies that target epigenetic regulators. The company's proprietary chemistry platform enables modulation of protein-protein interactions implicated in oncology and neurodegenerative diseases. By focusing on high-unmet medical needs, SynuCa aims to develop first-in-class treatments for cancers and conditions like Alzheimer's disease. The company is currently in the preclinical stage, with a pipeline centered on novel epigenetic mechanisms that offer the potential for both monotherapy and combination approaches. The company's lead programs are advancing toward IND-enabling studies, with a focus on solid tumors and neurodegenerative indications. SynuCa's approach addresses key challenges in drug discovery by targeting previously undruggable targets. Early in vitro and in vivo data have shown promising efficacy and selectivity. With a strong focus on intellectual property and a seasoned management team, SynuCa is positioned to attract partnerships and further funding to accelerate development. The next 12-18 months are critical for validating its platform and advancing candidates toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate selection for oncology program70% success
• Q4 2026In vivo proof-of-concept data in neurodegenerative model50% success
• Q2 2027Series A financing round close60% success